Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19)

Urinary Biomarkers (TIMP-2 and IGFBP7) for Early Diagnostic Assessment of Acute Kidney Injury in Patients With SARS-CoV-2 (COVID-19)

Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.

Inclusion criteria:

• Age ≥ 18 years
• COVID-19 confirmed by positive SARS-CoV-2 PCR
• at least one urine sample

Exclusion criteria:

• Persons under protection
• Paritcipation rejections